American Association for Cancer Research
Browse
15357163mct110498-sup-fl5_pdf_57k.pdf (57.85 kB)

Supplementary Figure Legends 1-5 from Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells

Download (57.85 kB)
journal contribution
posted on 2023-04-03, 13:22 authored by Daina Z. Ewton, Jing Hu, Maria Vilenchik, Xiaobing Deng, Kin-chun Luk, Ann Polonskaia, Ann F. Hoffman, Karen Zipf, John F. Boylan, Eileen A. Friedman

PDF file - 57K

History

ARTICLE ABSTRACT

A major problem in the treatment of cancer arises from quiescent cancer cells that are relatively insensitive to most chemotherapeutic drugs and radiation. Such residual cancer cells can cause tumor regrowth or recurrence when they reenter the cell cycle. Earlier studies showed that levels of the serine/theronine kinase Mirk/dyrk1B are elevated up to 10-fold in quiescent G0 tumor cells. Mirk uses several mechanisms to block cell cycling, and Mirk increases expression of antioxidant genes that decrease reactive oxygen species (ROS) levels and increase quiescent cell viability. We now show that a novel small molecule Mirk kinase inhibitor blocked tumor cells from undergoing reversible arrest in a quiescent G0 state and enabled some cells to exit quiescence. The inhibitor increased cycling in Panc1, AsPc1, and SW620 cells that expressed Mirk, but not in HCT116 cells that did not. Mirk kinase inhibition elevated ROS levels and DNA damage detected by increased phosphorylation of the histone protein H2AX and by S-phase checkpoints. The Mirk kinase inhibitor increased cleavage of the apoptotic proteins PARP and caspase 3, and increased tumor cell kill several-fold by gemcitabine and cisplatin. A phenocopy of these effects occurred following Mirk depletion, showing drug specificity. In previous studies Mirk knockout or depletion had no detectable effect on normal tissue, suggesting that the Mirk kinase inhibitor could have a selective effect on cancer cells expressing elevated levels of Mirk kinase. Mol Cancer Ther; 10(11); 2104–14. ©2011 AACR.